SG10201708542RA - Anti-pdl1 antibody formulations - Google Patents
Anti-pdl1 antibody formulationsInfo
- Publication number
- SG10201708542RA SG10201708542RA SG10201708542RA SG10201708542RA SG10201708542RA SG 10201708542R A SG10201708542R A SG 10201708542RA SG 10201708542R A SG10201708542R A SG 10201708542RA SG 10201708542R A SG10201708542R A SG 10201708542RA SG 10201708542R A SG10201708542R A SG 10201708542RA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody formulations
- pdl1 antibody
- pdl1
- formulations
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361883953P | 2013-09-27 | 2013-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201708542RA true SG10201708542RA (en) | 2017-12-28 |
Family
ID=51703416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201602283UA SG11201602283UA (en) | 2013-09-27 | 2014-09-26 | Anti-pdl1 antibody formulations |
| SG10201708542RA SG10201708542RA (en) | 2013-09-27 | 2014-09-26 | Anti-pdl1 antibody formulations |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201602283UA SG11201602283UA (en) | 2013-09-27 | 2014-09-26 | Anti-pdl1 antibody formulations |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US10875922B2 (en) |
| EP (3) | EP4285928A3 (en) |
| JP (3) | JP6942465B2 (en) |
| KR (1) | KR102331663B1 (en) |
| CN (1) | CN105793288B (en) |
| AR (1) | AR097791A1 (en) |
| AU (3) | AU2014324703C1 (en) |
| BR (1) | BR112016006397B1 (en) |
| CA (1) | CA2925310C (en) |
| CL (1) | CL2016000680A1 (en) |
| CR (1) | CR20160141A (en) |
| DK (1) | DK3049441T3 (en) |
| EA (2) | EA201991715A1 (en) |
| ES (1) | ES2768614T3 (en) |
| HK (1) | HK1222867A1 (en) |
| HR (1) | HRP20200102T1 (en) |
| HU (1) | HUE047194T2 (en) |
| IL (3) | IL244712B (en) |
| LT (1) | LT3049441T (en) |
| MA (1) | MA38960A1 (en) |
| MX (3) | MX2016003939A (en) |
| MY (1) | MY175472A (en) |
| NZ (1) | NZ719036A (en) |
| PE (1) | PE20160541A1 (en) |
| PH (2) | PH12016500566A1 (en) |
| PL (1) | PL3049441T3 (en) |
| PT (1) | PT3049441T (en) |
| RS (1) | RS59880B1 (en) |
| SG (2) | SG11201602283UA (en) |
| SI (1) | SI3049441T1 (en) |
| TW (2) | TWI660738B (en) |
| UA (1) | UA122478C2 (en) |
| WO (1) | WO2015048520A1 (en) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210060670A (en) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US9427477B2 (en) | 2011-05-09 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| CA2917407C (en) | 2012-10-01 | 2023-03-14 | Mayo Foundation For Medical Education And Research | Complexes containing albumin-containing nanoparticles and antibodies to treat cancer |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| PE20160541A1 (en) | 2013-09-27 | 2016-06-03 | Genentech Inc | ANTI-PDL1 ANTIBODY FORMULATIONS |
| TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
| JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
| MX2016016617A (en) | 2014-06-16 | 2017-03-23 | Mayo Foundation | Treating myelomas. |
| CN107206071A (en) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | The conjoint therapy of ALK inhibitor |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| ES2952717T3 (en) | 2014-10-14 | 2023-11-03 | Novartis Ag | Antibody molecules against PD-L1 and uses thereof |
| MA42971A (en) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF |
| US10881733B2 (en) * | 2015-05-22 | 2021-01-05 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
| EP3356551B1 (en) | 2015-09-29 | 2020-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining the metabolic status of b-lymphomas |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| JP6983371B2 (en) | 2015-11-17 | 2021-12-17 | スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド | Anti-PD-L1 antibody, its antigen-binding fragment and its medical use |
| US11058769B2 (en) * | 2015-12-07 | 2021-07-13 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab |
| EP3400443B1 (en) | 2016-01-04 | 2020-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | Methods of treating cancer with interferon |
| CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TWI755395B (en) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | Combination of anti-pd-1 antibodies and radiation to treat cancer |
| CN109414500B (en) * | 2016-06-13 | 2022-02-25 | 奥美药业有限公司 | PD-L1 specific monoclonal antibody for treatment and diagnosis |
| EP3909985A1 (en) | 2016-06-27 | 2021-11-17 | MorphoSys AG | Anti-cd19 antibody formulations |
| WO2018027524A1 (en) * | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
| ES2937291T3 (en) | 2016-09-01 | 2023-03-27 | Mayo Found Medical Education & Res | Compositions of Agents That Bind to the PD-L1 Transporter and Methods of Using Them to Treat Cancers |
| KR20190053203A (en) | 2016-09-01 | 2019-05-17 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | Methods and compositions for targeting T-cell cancers |
| MX2019002564A (en) | 2016-09-06 | 2019-09-18 | Mayo Found Medical Education & Res | Paclitaxel-albumin-binding agent compositions and methods for using and making the same. |
| AU2017324335A1 (en) * | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Methods of treating PD-L1 expressing cancer |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | Methods of treating vitiligo using pd-1 binding proteins |
| US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
| AU2018229724A1 (en) * | 2017-03-06 | 2019-10-31 | Merck Patent Gmbh | Aqueous anti-PD-L1 antibody formulation |
| WO2018172508A1 (en) | 2017-03-24 | 2018-09-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| US20180289802A1 (en) * | 2017-03-29 | 2018-10-11 | Celgene Corporation | Formulations comprising pd-1 binding proteins and methods of making thereof |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| RU2766590C2 (en) | 2017-05-16 | 2022-03-15 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Pharmaceutical composition based on antibody to pd-l1 and its application |
| EP3624846A1 (en) | 2017-05-16 | 2020-03-25 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| JP2020522486A (en) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | Activatable anti-PDL1 antibody and method of using the same |
| CN107384870A (en) * | 2017-07-31 | 2017-11-24 | 时力生物科技（北京）有限公司 | A kind of T lymphocytes of targeting PD L1 Chimeric antigen receptors modification and its preparation method and application |
| CN111328286A (en) | 2017-08-09 | 2020-06-23 | 奥里尼斯生物科学有限公司 | PD-1 and PD-L1 binding agents |
| US20200216542A1 (en) * | 2017-09-20 | 2020-07-09 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
| US20200237906A1 (en) * | 2017-11-02 | 2020-07-30 | Nanjing Shunxin Pharmaceutical Co., Ltd. | Pharmaceutical Composition of Humanized Monoclonal Anti-PD-L1 Antibody |
| WO2019134946A1 (en) | 2018-01-04 | 2019-07-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma resistant |
| US11359021B2 (en) | 2018-01-10 | 2022-06-14 | Jiangsu Hengrui Medicine Co., Ltd. | PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| US20210080467A1 (en) | 2018-02-21 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors |
| CN112105343A (en) * | 2018-03-07 | 2020-12-18 | 辉瑞公司 | anti-PD-1 antibody compositions |
| US20210253614A1 (en) | 2018-05-31 | 2021-08-19 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
| JP2021525806A (en) * | 2018-06-01 | 2021-09-27 | タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド | Compositions for treating diseases or conditions and their use |
| EP3818082A1 (en) * | 2018-07-04 | 2021-05-12 | F. Hoffmann-La Roche AG | Novel bispecific agonistic 4-1bb antigen binding molecules |
| EP3843849A1 (en) | 2018-08-27 | 2021-07-07 | Pieris Pharmaceuticals GmbH | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
| BR112021008774A2 (en) * | 2018-11-06 | 2021-11-30 | BioNTech SE | Pharmaceutical formulation, binding agent, methods for treating a disease, for producing a pharmaceutical formulation, for inducing cell death or inhibiting the growth and/or proliferation of a tumor cell, and, use of a pharmaceutical formulation |
| WO2020104479A1 (en) | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
| US20230183379A1 (en) | 2018-11-20 | 2023-06-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Bispecific antibody targeting transferrin receptor 1 and soluble antigen |
| US20230287122A1 (en) * | 2018-11-29 | 2023-09-14 | Harbour Biomed Therapeutics Limited | Anti-pd-l1 antibody preparation |
| WO2020116636A1 (en) | 2018-12-07 | 2020-06-11 | 小野薬品工業株式会社 | Immunosuppressant |
| WO2020115261A1 (en) | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| EP3894401A2 (en) | 2018-12-11 | 2021-10-20 | Theravance Biopharma R&D IP, LLC | Naphthyridine and quinoline derivatives useful as alk5 inhibitors |
| WO2020120592A1 (en) | 2018-12-12 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating melanoma |
| EP3898699A1 (en) | 2018-12-19 | 2021-10-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d |
| WO2020127885A1 (en) | 2018-12-21 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for treating cancers and resistant cancers |
| WO2020157131A1 (en) | 2019-01-30 | 2020-08-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor |
| WO2020161083A1 (en) | 2019-02-04 | 2020-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating blood-brain barrier |
| US20220098674A1 (en) | 2019-02-13 | 2022-03-31 | Inserm (Institut National De La Santé Et Dr La Recherch Médicale) | Methods and compositions for selecting a cancer treatment in a subject suffering from cancer |
| CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
| CN109929037B (en) | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | Conjugates to programmed death ligands and uses thereof |
| US20220220565A1 (en) | 2019-04-30 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| WO2021048292A1 (en) | 2019-09-11 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| WO2021064180A1 (en) | 2019-10-03 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating macrophages polarization |
| EP4045686A1 (en) | 2019-10-17 | 2022-08-24 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosing nasal intestinal type adenocarcinomas |
| EP4032908A4 (en) | 2019-10-21 | 2023-11-08 | HC Biopharma (Shanghai) Co., Ltd | Anti-pd-l1 antibody and pharmaceutical use thereof |
| WO2021083959A1 (en) | 2019-10-29 | 2021-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating uveal melanoma |
| CN114728941A (en) | 2019-11-22 | 2022-07-08 | 施万生物制药研发Ip有限责任公司 | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors |
| MX2022006784A (en) * | 2019-12-09 | 2022-07-11 | Genentech Inc | Anti-pd-l1 antibody formulations. |
| AU2020408198A1 (en) | 2019-12-19 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and vaccine compositions to treat cancers |
| EP4090770A1 (en) | 2020-01-17 | 2022-11-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| WO2021156360A1 (en) | 2020-02-05 | 2021-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki) |
| EP4110955A1 (en) | 2020-02-28 | 2023-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, prognosing and managing treatment of breast cancer |
| US11673879B2 (en) | 2020-03-31 | 2023-06-13 | Theravance Biopharma R&D Ip, Llc | Substituted pyrimidines and methods of use |
| TW202214623A (en) | 2020-06-10 | 2022-04-16 | 美商施萬生物製藥研發 Ip有限責任公司 | Crystalline alk5 inhibitors and uses thereof |
| JP2023535610A (en) | 2020-07-28 | 2023-08-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and compositions for preventing and treating cancer |
| US11865082B2 (en) | 2020-09-09 | 2024-01-09 | Hoffmann-La Roche Inc. | Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 |
| WO2022084531A1 (en) | 2020-10-23 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating glioma |
| WO2022101481A1 (en) | 2020-11-16 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
| US20230416838A1 (en) | 2020-11-16 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
| JP2024500847A (en) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | Chimeric antigen receptor systems with compatible receptor specificities |
| US20240165094A1 (en) | 2021-03-17 | 2024-05-23 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating melanoma |
| EP4326903A1 (en) | 2021-04-23 | 2024-02-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating cell senescence accumulation related disease |
| WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
| WO2023078900A1 (en) | 2021-11-03 | 2023-05-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating triple negative breast cancer (tnbc) |
| AR127912A1 (en) * | 2021-12-08 | 2024-03-06 | Ferring Bv | PROTEIN PURIFICATION METHOD BY PRECIPITATION |
| WO2023118165A1 (en) | 2021-12-21 | 2023-06-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| WO2024033400A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sk2 inhibitor for the treatment of pancreatic cancer |
| WO2024033399A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sigmar1 ligand for the treatment of pancreatic cancer |
| WO2024056716A1 (en) | 2022-09-14 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy |
| WO2024084034A1 (en) | 2022-10-21 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of osteoarthritis |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (en) | 1978-01-06 | 1979-08-03 | David Bernard | DRYER FOR SCREEN-PRINTED SHEETS |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DD266710A3 (en) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Process for the biotechnical production of alkaline phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| FR2646437B1 (en) | 1989-04-28 | 1991-08-30 | Transgene Sa | NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| DK0479909T3 (en) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecific reagents for AIDS treatment |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DK0546073T3 (en) | 1990-08-29 | 1998-02-02 | Genpharm Int | Production and use of transgenic, non-human animals capable of forming heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE164395T1 (en) | 1990-12-03 | 1998-04-15 | Genentech Inc | METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| ATE196606T1 (en) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE69637481T2 (en) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Human antibodies to IL-8 derived from immunized Xenomae |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6498236B1 (en) | 1996-08-30 | 2002-12-24 | Upfront Chromatography A/S | Isolation of immunoglobulins |
| ATE387495T1 (en) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | FULLY HUMANE ANTIBODIES THAT BIND EGFR |
| US20080318254A9 (en) | 1997-03-10 | 2008-12-25 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| PT1034298E (en) | 1997-12-05 | 2012-02-03 | Scripps Research Inst | Humanization of murine antibody |
| AU754808B2 (en) | 1999-03-30 | 2002-11-28 | Amgen Fremont Inc. | Method for preparing Monoclonal Antibody |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ATE303445T1 (en) | 1999-10-04 | 2005-09-15 | Medicago Inc | METHOD FOR REGULATION OF TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN |
| US7144723B2 (en) * | 2000-11-16 | 2006-12-05 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
| WO2002092017A2 (en) | 2001-05-16 | 2002-11-21 | Albert Einstein College Of Medicine Of Yeshiva University | Human antipneumococcal antibodies from non-human animals |
| BR0212136A (en) | 2001-08-23 | 2004-12-07 | Genmab As | Isolated human monoclonal antibody, methods for inhibiting tnfa production in t cells or monocytes and t cell proliferation, hybridoma, transfectoma, transgenic non-human animal, method for producing a human monoclonal antibody, pharmaceutical composition, methods for treating or preventing a human il-15 mediated disorder, psoriasis and rheumatoid arthritis, method for diagnosing a disease, nucleic acid, and expression vector |
| AU2004205898B2 (en) | 2003-01-17 | 2009-11-19 | The Research Foundation Of State University Of New York | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| MXPA05012571A (en) | 2003-05-21 | 2006-02-08 | Medarex Inc | Human monoclonal antibodies against bacillusanthracis. |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| KR20210060670A (en) * | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| BR112012033457A2 (en) * | 2010-07-02 | 2017-04-04 | Medimmune Llc | antibody formulations. |
| JP5987053B2 (en) | 2011-05-12 | 2016-09-06 | ジェネンテック， インコーポレイテッド | Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides |
| WO2013019906A1 (en) * | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| HUE051954T2 (en) * | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| CA2859755C (en) * | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| SG11201509742QA (en) | 2013-06-03 | 2015-12-30 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| PE20160541A1 (en) | 2013-09-27 | 2016-06-03 | Genentech Inc | ANTI-PDL1 ANTIBODY FORMULATIONS |
| TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
-
2014
- 2014-09-26 PE PE2016000416A patent/PE20160541A1/en unknown
- 2014-09-26 TW TW103133659A patent/TWI660738B/en active
- 2014-09-26 CN CN201480064099.XA patent/CN105793288B/en active Active
- 2014-09-26 BR BR112016006397-0A patent/BR112016006397B1/en active IP Right Grant
- 2014-09-26 HU HUE14784169A patent/HUE047194T2/en unknown
- 2014-09-26 AU AU2014324703A patent/AU2014324703C1/en active Active
- 2014-09-26 RS RS20200089A patent/RS59880B1/en unknown
- 2014-09-26 EP EP23194749.0A patent/EP4285928A3/en active Pending
- 2014-09-26 JP JP2016517363A patent/JP6942465B2/en active Active
- 2014-09-26 EA EA201991715A patent/EA201991715A1/en unknown
- 2014-09-26 PT PT147841696T patent/PT3049441T/en unknown
- 2014-09-26 PL PL14784169T patent/PL3049441T3/en unknown
- 2014-09-26 MY MYPI2016000534A patent/MY175472A/en unknown
- 2014-09-26 KR KR1020167010636A patent/KR102331663B1/en active IP Right Grant
- 2014-09-26 NZ NZ719036A patent/NZ719036A/en unknown
- 2014-09-26 CA CA2925310A patent/CA2925310C/en active Active
- 2014-09-26 EA EA201690667A patent/EA033817B1/en not_active IP Right Cessation
- 2014-09-26 SI SI201431471T patent/SI3049441T1/en unknown
- 2014-09-26 LT LTEP14784169.6T patent/LT3049441T/en unknown
- 2014-09-26 WO PCT/US2014/057821 patent/WO2015048520A1/en active Application Filing
- 2014-09-26 SG SG11201602283UA patent/SG11201602283UA/en unknown
- 2014-09-26 EP EP14784169.6A patent/EP3049441B1/en active Active
- 2014-09-26 SG SG10201708542RA patent/SG10201708542RA/en unknown
- 2014-09-26 TW TW108108366A patent/TWI714022B/en active
- 2014-09-26 ES ES14784169T patent/ES2768614T3/en active Active
- 2014-09-26 EP EP19199570.3A patent/EP3626742A1/en not_active Withdrawn
- 2014-09-26 DK DK14784169.6T patent/DK3049441T3/en active
- 2014-09-26 MX MX2016003939A patent/MX2016003939A/en active IP Right Grant
- 2014-09-26 UA UAA201604644A patent/UA122478C2/en unknown
- 2014-09-26 AR ARP140103581A patent/AR097791A1/en not_active Application Discontinuation
- 2014-09-26 MA MA38960A patent/MA38960A1/en unknown
-
2016
- 2016-03-22 IL IL244712A patent/IL244712B/en active IP Right Grant
- 2016-03-23 CL CL2016000680A patent/CL2016000680A1/en unknown
- 2016-03-23 MX MX2022014781A patent/MX2022014781A/en unknown
- 2016-03-23 MX MX2020010026A patent/MX2020010026A/en unknown
- 2016-03-25 US US15/081,785 patent/US10875922B2/en active Active
- 2016-03-28 PH PH12016500566A patent/PH12016500566A1/en unknown
- 2016-03-29 CR CR20160141A patent/CR20160141A/en unknown
- 2016-09-21 HK HK16111065.9A patent/HK1222867A1/en unknown
-
2019
- 2019-06-05 JP JP2019104978A patent/JP2019194195A/en not_active Withdrawn
- 2019-08-20 PH PH12019501931A patent/PH12019501931A1/en unknown
- 2019-10-24 IL IL270165A patent/IL270165B/en unknown
-
2020
- 2020-01-21 HR HRP20200102TT patent/HRP20200102T1/en unknown
- 2020-05-19 AU AU2020203267A patent/AU2020203267B2/en active Active
- 2020-11-23 US US17/101,966 patent/US20210221892A1/en not_active Abandoned
-
2021
- 2021-06-29 JP JP2021107154A patent/JP2021169458A/en not_active Withdrawn
- 2021-08-09 IL IL285474A patent/IL285474A/en unknown
-
2022
- 2022-09-23 AU AU2022235627A patent/AU2022235627A1/en active Pending
-
2023
- 2023-08-02 US US18/364,312 patent/US20240010732A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202005525B (en) | Antibody formulations | |
| IL269528A (en) | Anti-fcrh5 antibodies | |
| IL244712A0 (en) | Anti-pdl1 antibody formulations | |
| EP3065716C0 (en) | Formulations | |
| GB201322583D0 (en) | Antibodies | |
| IL244043A0 (en) | Antibodies | |
| GB201308658D0 (en) | Antibodies | |
| GB201319792D0 (en) | Formulations | |
| GB201315486D0 (en) | Antibodies | |
| GB201300706D0 (en) | Antibody | |
| HK1214951A1 (en) | Ophthalimic formulations | |
| IL245488A0 (en) | Anti-ccl17 antibodies | |
| GB201318283D0 (en) | Antibodies |